{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:54:04Z","timestamp":1772816044127,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.clinthera.2004.12.006","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T12:26:37Z","timestamp":1110543997000},"page":"2121-2127","source":"Crossref","is-referenced-by-count":5,"title":["Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: A randomized, controlled, investigator-blinded study"],"prefix":"10.1016","volume":"26","author":[{"given":"Ricardo","family":"Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia Cristina","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos P.","family":"vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopoldo","family":"Magacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2004.12.006_bib1","series-title":"Glaucoma prim rio de ngulo aberto. I Consenso da sociedade brasileira de glaucoma","first-page":"1","article-title":"Conceito, press o intra-ocular, outros fatores de risco e diagn stico","author":"Silva","year":"2001"},{"key":"10.1016\/j.clinthera.2004.12.006_bib2","first-page":"1","article-title":"An overview of glaucoma","author":"Shields","year":"2000"},{"key":"10.1016\/j.clinthera.2004.12.006_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0002-9394(99)00387-6","article-title":"Intraocular pressure and progression of glaucomatous visual field loss","volume":"129","author":"Martinez-Bello","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0161-6420(00)00021-X","article-title":"Target pressure\u2014glaucomatologists' holy grail","volume":"107","author":"Singh","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2004.12.006_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archopht.117.5.573","article-title":"The Ocular Hypertension Treatment Study: Design and baseline description of the participants","volume":"117","author":"Gordom","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0002-9394(14)76896-5","article-title":"Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma","volume":"111","author":"Mao","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib9","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archopht.1995.01100070092031","article-title":"Risk factors for open-angle glaucoma","volume":"113","author":"Leske","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib10","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1001\/archopht.1980.01020041015002","article-title":"Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects","volume":"98","author":"Armaly","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0161-6420(82)34675-8","article-title":"Why do some people go blind from glaucoma?","volume":"89","author":"Grant","year":"1982","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2004.12.006_bib12","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","first-page":"43","article-title":"Principles of therapeutics","author":"Hardman","year":"1996"},{"key":"10.1016\/j.clinthera.2004.12.006_bib13","first-page":"1","article-title":"Travatan (travoprost 0,004% ophthalmic solution)","year":"2001"},{"key":"10.1016\/j.clinthera.2004.12.006_bib14","series-title":"Travatan (travoprost 0,004% ophthalmic solution)","year":"2001"},{"key":"10.1016\/j.clinthera.2004.12.006_bib15","first-page":"1","volume":"153","year":"2004"},{"key":"10.1016\/j.clinthera.2004.12.006_bib16","series-title":"Processo no 25.165\/2001, natureza: Determina o do n mero de gotas contidas em frasco de col rio. Metodologia: Contagem direta das gotas contidas em cada frasco. Execu o e Supervis o: Pedro Antonio Zanoto e Gilvani Silvestre","author":"IPEM-SP (Instituto de Pesos e Medidas do Estado de Sao Paulo)","year":"2001"},{"key":"10.1016\/j.clinthera.2004.12.006_bib17","series-title":"Clinical Decisions in Glaucoma","year":"1993"},{"key":"10.1016\/j.clinthera.2004.12.006_bib18","series-title":"The Optic Nerve in Glaucoma","author":"Varma","year":"1993"},{"key":"10.1016\/j.clinthera.2004.12.006_bib19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9394(01)01337-X","article-title":"A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or hypertension ocular. 6 Month data","volume":"133","author":"Nordmann","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0149-2918(00)89008-6","article-title":"Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma","volume":"22","author":"Simmons","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2004.12.006_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bjo.79.1.12","article-title":"Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol","volume":"79","author":"Alm","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2004.12.006_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1475-1313.1993.tb00491.x","article-title":"Investigation of parameters influencing intraocular pressure increases during sleep","volume":"13","author":"Wildsoet","year":"1993","journal-title":"Ophthalmic Physiol Opt."},{"key":"10.1016\/j.clinthera.2004.12.006_bib24","series-title":"The Glaucomas","first-page":"429","article-title":"Circadian variations in intraocular pressure","author":"Zeimer","year":"1996"},{"key":"10.1016\/j.clinthera.2004.12.006_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A 6-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291804000761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291804000761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T07:22:07Z","timestamp":1548660127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291804000761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0149291804000761"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2004.12.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}